Novel therapeutic approaches for chronic kidney disease due to glomerular disorders.

Improved understanding of glomerular disease mechanisms over the past decade has led to the emergence of new and targeted therapeutic strategies for chronic kidney disease (CKD). Most promising among these are the administration of recombinant mutated human angiopoietin-like 4, sialic acid-related sugars that induce sialylation in vivo, compounds related to Bis-T-23, and immune depletion of the soluble urokinase receptor from the circulation. Taking these therapeutic strategies into clinical trials will be the first step away from repurposed and relatively toxic drugs currently used for treating kidney disease.

[1]  A. Quyyumi,et al.  Soluble Urokinase Receptor and Chronic Kidney Disease. , 2015, The New England journal of medicine.

[2]  C. B. Marshall,et al.  The proteinuria-hypertriglyceridemia connection as a basis for novel therapeutics for nephrotic syndrome. , 2015, Translational research : the journal of laboratory and clinical medicine.

[3]  M. Selig,et al.  Pharmacological targeting of actin-dependent dynamin oligomerization ameliorates chronic kidney disease in diverse animal models , 2015, Nature Medicine.

[4]  L. Lerman,et al.  Biomarkers of kidney injury and klotho in patients with atherosclerotic renovascular disease. , 2015, Clinical journal of the American Society of Nephrology : CJASN.

[5]  G. London,et al.  Ankle-brachial index and bone turnover in patients on dialysis. , 2015, Journal of the American Society of Nephrology : JASN.

[6]  S. Chugh,et al.  Nephrotic syndrome: components, connections, and angiopoietin-like 4-related therapeutics. , 2014, Journal of the American Society of Nephrology : JASN.

[7]  C. B. Marshall,et al.  Angiopoietin-like 4 based therapeutics for proteinuria and kidney disease , 2014, Front. Pharmacol..

[8]  S. Kersten,et al.  Circulating angiopoietin-like 4 links proteinuria with hypertriglyceridemia in nephrotic syndrome , 2013, Nature Medicine.

[9]  S. Chugh,et al.  New insights into human minimal change disease: lessons from animal models. , 2012, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[10]  E. Salido,et al.  Circulating urokinase receptor as a cause of focal segmental glomerulosclerosis , 2011, Nature Medicine.

[11]  S. Kersten,et al.  Podocyte secreted Angiopoietin-like 4 mediates proteinuria in glucocorticoid sensitive nephrotic syndrome , 2010, Nature Medicine.

[12]  Y. Kanwar,et al.  Early changes in gene expression that influence the course of primary glomerular disease. , 2007, Kidney international.

[13]  B. Bammens,et al.  Soluble urokinase receptor is a biomarker of cardiovascular disease in chronic kidney disease. , 2015, Kidney international.